Morningside: The Chan Family's Life-Sciences VC — and the Story of the 5Y Capital Rebrand

Morningside is one of the more misunderstood names in venture capital — and the confusion costs founders time. The name belongs to a private investment group founded in 1986 by the Chan family of Hong Kong (co-founded by Gerald Chan and his brother Ronnie Chan, of the Hang Lung property group). What many call "Morningside Ventures" or "Morningside Venture Capital" is actually a family of related vehicles that split apart in 2020, so picking the right door matters.

The family-office group's own venture activity — Morningside Ventures — focuses on technology and life sciences, investing globally out of offices in Boston, Shanghai and London. It positions itself as a partner to academic founders and entrepreneurs building companies that, in its words, seek to markedly improve the current state of medicine. The group began investing in China in 1992 and has long been active in China's internet, media and life-science sectors.

The more famous part of the Morningside story is the China TMT arm, Morningside Venture Capital, founded in 2008 by Richard Liu and Ken Shi (both formerly investment professionals at Morningside Group) under Morningside Group's auspices, with the group as anchor investor. It was the first institutional backer of Xiaomi — an investment reported to have delivered an approximately 800x return — and its portfolio included UCWeb, YY (Joyy), Kuaishou, Huami, Musical.ly, Horizon Robotics, Huya, Pony.ai and Xpeng Motors. In October 2020 this operation formally separated from Morningside Group and rebranded as 5Y Capital, named for Wuyuan Road in Shanghai where the team has always been headquartered. Morningside Group remains one of 5Y Capital's most important investors.

On the life-sciences side, the firm's recent company-building is well documented. Morningside launched Adiso Therapeutics, rolling two of its biotech investments into a clinical-phase inflammatory-disease company. It co-led a $28.5 million Series A for Vesigen Therapeutics alongside Leaps by Bayer, with Gerald Chan named chairman, and led the Series B for Immune Regulation, the UK/US immune-resetting biotech. Other biotech bets include AdvanCell (its A$18 million Series B), Apellis, Amylyx, Curai Health, MicuRx and Genocea. Founder-facing individuals named in the firm's deal announcements include Isaac Cheng, M.D. and Stephen Bruso.

For Indian founders, the India connection is worth parsing carefully. Morningside invested in Cashify (Series C), ShareChat (a $100 million round alongside Shunwei Capital and a DST Global affiliate) and CRED — but these deals were made by Morningside Venture Capital, i.e. the team that is now 5Y Capital, which in 2019 moved investment manager Hanson Hu to Bengaluru to hunt for what it called "outliers" and homegrown Indian ideas, from re-commerce (Cashify, paired with its Chinese counterpart AiHuiShou) to vernacular social (ShareChat) to fintech (CRED). Founders approaching the "Morningside" brand on Indian deals today should therefore route themselves to 5Y Capital, not the family group's life-sciences arm.

The firm's fund size is not publicly disclosed — it operates as a private family investment group rather than a conventional fundraising GP — and it advertises no founder programmes, credits or perks. Its edge is patient, science-led company building and cross-pollination between its Chinese, American and European portfolio companies rather than accelerator-style volume investing.